Towa Pharmaceutical (TSE:4553) Valuation After Goodwill Impairment And FY2027 Recovery Outlook

Goodwill impairment hits guidance while dividend and FY2027 outlook steady

Towa Pharmaceutical (TSE:4553) drew investor attention after announcing a large goodwill impairment at subsidiary Sunsho Pharmaceutical, which led to sharply reduced FY2026 profit guidance and raised questions about near term earnings quality.

At the same time, the company kept its dividend plan unchanged and outlined expectations for higher sales and profit in FY2027. This combination puts the focus on how quickly core operations can offset the impact of the impairment.

See our latest analysis for Towa Pharmaceutical.

The goodwill impairment disclosure has been a clear catalyst, with the share price jumping 10.04% over the last day to ¥3,780 but still sitting down 12.80% over 30 days. Over longer periods, a 36.91% 1-year total shareholder return and 111.17% 3-year total shareholder return point to momentum that has so far remained intact.

If this kind of rebound on news has you thinking about where else sentiment could shift next, it might be worth scanning 12 top founder-led companies

With goodwill written down, FY2026 guidance cut and FY2027 recovery plans on the table, the key question for you is simple: is Towa’s current valuation a genuine opening or already reflecting brighter years ahead?

Price-to-earnings of 8.7x: Is it justified?

Towa Pharmaceutical closed at ¥3,780 and is flagged as trading at good value on an 8.7x P/E ratio compared with both the wider JP market and its Pharmaceuticals peers.

The P/E ratio compares the share price with earnings per share, so a lower figure can indicate the market is paying less for each unit of current earnings. For a pharmaceutical company with established products and ongoing R&D, earnings quality and consistency matter just as much as the headline multiple.

Here, Towa scores well on several fronts that relate directly to the earnings behind that 8.7x P/E. Earnings have grown by 11.2% over the past year and by 8.3% per year over the past 5 years, and recent profit margins of 7.9% are slightly higher than last year’s 7.6%. Those earnings are also assessed as high quality, which can give some context to why the stock is considered good value rather than simply cheap.

The comparison with peers is also clear. Towa’s 8.7x P/E is below the JP market’s 14.3x, below the Pharmaceuticals industry average of 16x, and below an estimated fair P/E of 16.7x from the SWS fair ratio model. That is a wide gap. The fair ratio represents a level the market could move towards if earnings and sentiment align with that benchmark.

Explore the SWS fair ratio for Towa Pharmaceutical

Result: Price-to-earnings of 8.7x (UNDERVALUED)

However, recent goodwill impairment, reduced FY2026 profit guidance, and questions around Sunsho’s contribution could still pressure sentiment if execution stumbles.

Find out about the key risks to this Towa Pharmaceutical narrative.

Another view: DCF points the other way

While the 8.7x P/E ratio presents Towa as inexpensive compared with peers, the SWS DCF model suggests a different picture. With the share price at ¥3,780 and an estimated future cash flow value of ¥1,518.37, the stock is described as trading well above that DCF estimate. So which signal is more important for your own assessment?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Towa Pharmaceutical for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 22 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

If this mix of pressure and potential leaves you undecided, move quickly to review the underlying data yourself and weigh both sides of the story with the 5 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Towa has sharpened your focus, do not stop here. Broaden your watchlist now so you are not the one hearing about opportunities after they move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com